Table 4 Clinical, functional, survival and baseline data of patients with CPFE and ANA + ANCA + immunologic profile with and without positive renal biopsy for MPA
From: Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema
Variable | ANA + ANCA + with positive renal biopsy for MPA | ANA + ANCA + without positive renal biopsy for MPA |
|---|---|---|
Patients (n) | 3 | 4 |
Renal function | Renal failure | normal |
Hematuria (n) | 3 | 4 |
Hemoptysis (n) | 2 | 0 |
Gas exchange impairment | Respiratory failure | Mild |
Treatment | Pulses of methyprednisolone (1gr for 3 consecutive days) and cyclophosphamide (1gr for one day) plus oral cyclophosphamide (60 mgr/day) and oral prednisolone (60 mg/day) for 7 months | Azathioprine (2mg/kgr/day), prednisolone (20mgr/day), NAC (1800mgr/day) for 12 months |
Death | 1 | 0 |
FVC%pred. before Rx (∫) | 60,5 ± 18,8 | 76,2 ± 24,5 |
FVC%pred. after Rx (§) | 57,8 ± 17,1 | 70,3 ± 21,8 |
DLCO%pred. before Rx (∫) | 29,5 ± 9,8 | 37,3 ±11,2 |
DLCO%pred. after Rx (§) | 26,5 ± 10,1 | 35,9 ± 10,9 |